argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

argenx SE

Product Net Sales

Product Net Sales %Chg

Product Net Sales Common Size

Collaboration Revenue

Collaboration Revenue %Chg

Collaboration Revenue Common Size

Other Operating Income

Other Operating Income %Chg

Other Operating Income Common Size

Revenue

Revenue %Chg

Revenue Common Size

Total Operating Income

Total Operating Income %Chg

Total Operating Income Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Research and Development Expenses

Research and Development Expenses %Chg

Research and Development Expenses Common Size

Selling, General and Administrative Expenses

Selling, General and Administrative Expenses %Chg

Selling, General and Administrative Expenses Common Size

Loss from Investment in a Joint Venture

Loss from Investment in a Joint Venture %Chg

Loss from Investment in a Joint Venture Common Size

Total Operating Expenses

Total Operating Expenses %Chg

Total Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Financial Income/(Expenses)

Financial Income/(Expenses) %Chg

Financial Income/(Expenses) Common Size

Financial Income

Financial Income %Chg

Financial Income Common Size

Financial Expense

Financial Expense %Chg

Financial Expense Common Size

Exchange Gains/(Losses)

Exchange Gains/(Losses) %Chg

Exchange Gains/(Losses) Common Size

Loss Before Taxes

Loss Before Taxes %Chg

Loss Before Taxes Common Size

Profit for the Period Before Taxes

Profit for the Period Before Taxes %Chg

Profit for the Period Before Taxes Common Size

Income Tax (Expense)/Benefit

Income Tax (Expense)/Benefit %Chg

Income Tax (Expense)/Benefit Common Size

Profit for the Period

Profit for the Period %Chg

Profit for the Period Common Size

Owners of the Parent

Owners of the Parent %Chg

Owners of the Parent Common Size

Weighted Average Number of Shares Outstanding

Weighted Average Number of Shares Outstanding %Chg

Weighted Average Number of Shares Outstanding Common Size

Basic and Diluted Earnings per Share

Basic and Diluted Earnings per Share %Chg

Basic and Diluted Earnings per Share Common Size

Weighted Average Number of Shares Used for Basic Profit per Share

Weighted Average Number of Shares Used for Basic Profit per Share %Chg

Weighted Average Number of Shares Used for Basic Profit per Share Common Size

Basic Profit per Share

Basic Profit per Share %Chg

Basic Profit per Share Common Size

Weighted Average Number of Shares Used for Diluted Profit per Share

Weighted Average Number of Shares Used for Diluted Profit per Share %Chg

Weighted Average Number of Shares Used for Diluted Profit per Share Common Size

Diluted Profit per Share

Diluted Profit per Share %Chg

Diluted Profit per Share Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Common Shareholders

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	3,687.1	3,124.7	2,646.9	2,252	1,908.7	1,659.6
Total Revenues %Chg	93.2%	88.3%	82.4%	77.5%	84.8%	97.7%
Product Net Sales
Collaboration Revenue
Other Operating Income
Revenue
Cost of Sales	373.6	323.3	264.9	227.3	194.1	171
Cost of Sales
Gross Profit	3,313.5	2,801.4	2,382	2,024.8	1,714.5	1,488.6
Gross Profit Margin	89.9%	89.7%	90%	89.9%	89.8%	89.7%
Selling, General & Administrative Expenses	1,223.4	1,164.8	1,095.6	1,055.3	978.2	892.5
Selling, General and Administrative Expenses
Research & Development Expenses	1,289.6	1,169.9	1,067.5	983.4	992.6	948.4
Research and Development Expenses
Other Operating Expenses	11.2	9.4	8.2	7.6	7.1	5.8
Loss from Investment in a Joint Venture
Operating Profit	789.2	457.2	210.7	-21.7	-263.3	-358.1
Operating Profit
Operating Margin	21.4%	14.6%	8%	-1%	-13.8%	-21.6%
Interest and Investment Income	157.3	155.2	155.7	157.5	158.7	148.2
Financial Income
Interest Expense	-4	-3.6	-3.1	-2.5	-2	-1.6
Financial Expense
Non-Operating Income	19.2	55	-1.5	-48.2	44.1	-22.3
Exchange Gains/(Losses)
Financial Income/(Expenses)
Total Non-Operating Income	172.6	206.6	151.2	106.8	200.8	124.3
Income Before Provision for Income Taxes	961.8	663.8	361.9	85.2	-62.5	-233.8
Profit for the Period Before Taxes
Loss Before Taxes
Provision for Income Taxes	-571.4	-616.6	-702.2	-747.9	-22.2	-29.5
Income Tax (Expense)/Benefit
Consolidated Net Income	1,533.2	1,280.4	1,064.1	833	-40.3	-204.3
Profit for the Period
Net Income Attributable to Common Shareholders	1,533.2	1,280.4	1,064.1	833	-40.3	-204.3
Owners of the Parent
Basic EPS	25.2	21.1	17.6	13.9	-0.7	-3.5
Diluted EPS	23.3	19.5	16.2	12.8	-0.9	-3.5
Basic Weighted Average Shares Outstanding	61	60.7	60.3	59.9	59.5	59
Total Shares Outstanding	61.2	61.2	61	60.8	59.8	59.8
Diluted Weighted Average Shares Outstanding	65.9	65.7	65.2	65.2	62	60.1
EBITDA	789.2	479.4	230.6	-4.1	-195.9	-240.9
Effective Tax Rate	-59.4%	-92.9%	-194%	-878%	35.5%	12.6%